Pharmaceutical - Antibiotics and Infectious diseases, Gilead Sciences

Filter

Popular Filters

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

EMA advisory unit issues bunch of positive recommendations

EMA advisory unit issues bunch of positive recommendations

22-11-2013

At its late November meetings, the European Medicines Agency’s Committee for Medicinal Products for…

AB ScienceAnti-viralsAntibiotics and Infectious diseasesAstraZenecaBristol-Myers SquibbDeltybaDiabetesEuropeGilead SciencesLucaneLucane PharmaMasicanOncologyOtsukaPharmaceuticalRegulationSovaldiTivicayViiV HealthcareXigduo

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Parexel

Parexel

Back to top